Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients

March 2020

Crizanlizumab (Adakveo, ah-DAK-vee-oh) and voxelotor (Oxbryta, oks-BRYE-tuh) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they'll compete with oral L-glutamine (Endari)...which seems to reduce pain crises and possibly hospitalizations.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote